A weekly trade journal catering to the Indian chemical industry
backBack

calendar 9 July, 2024 15:04:26 IST

AstraZeneca to invest Rs. 250-crore on expansion of technology centre in Chennai

Article image

AstraZeneca India Pvt. Ltd. (AZIPL), the global capability centre (GCC) of British-Swedish drugmaker AstraZeneca, has announced an investment of Rs. 250-crore ($30-mn) to expand its Global Innovation and Technology Centre (GITC) in Chennai. The expansion includes adding close to 1,300 job roles focused on driving innovation, enhancing efficiency, and streamlining operations across the company globally.

The facility currently occupies 334,000 square feet of office space at Ramanujan IT City, with plans to add approximately 180,000 square feet over the next six months to accommodate this expansion, creating AstraZeneca’s biggest global capability centre. The expanded GITC will leverage technologies such as enterprise platforms, artificial intelligence, machine learning, data science, and supply chain analytics to shape healthcare outcomes.

The inauguration of the expanded facility was officiated by Tamil Nadu Minister of Industries Mr. TRB Rajaa, British Deputy High Commissioner to India Ms. Christina Scott CMG, and AstraZeneca’s Vice President for Asia Area Ms. Sylvia Varela.

Since its inception, the GITC in Chennai has evolved from providing traditional information technology support services to becoming an engine of AstraZeneca’s digital journey, driving productivity, simplification, technology delivery, and innovation across the company’s global operations, supporting the delivery of life-changing medicines to patients worldwide. Including GITC, AstraZeneca employs more than 4,000 people in the country.

Apart from being a hub for technology as well as research and development, AstraZeneca markets and distributes its portfolio in specialist disease areas including oncology, cardio-vascular, respiratory and rare disease. The investment marks AstraZeneca’s 45th year in India.

“Our expansion in Chennai signifies AstraZeneca’s unwavering commitment to pioneering science and innovation,” said Dr. Sanjeev Panchal, Managing Director & Country President AAIPL. “This strategic investment underscores our dedication to improving patient outcomes through cutting-edge technology and reinforces our aspiration to transform the future of the healthcare industry,” he added.

Mr. Siva Padmanabhan, Managing Director, AZIPL, said, “We are evolving our technologies constantly so that we can stay ahead of the curve in healthcare and pharmaceutical industries to better serve our patients in countries where we operate.”

article image
calender image

calender image 9 November, 2026 20:19:59 IST

Will India’s butadiene paradox resolve through integrated C4 value chain development?

India is at an important turning point in the development of its butadiene value chain. For years, the country...
article image

calender image 13 November, 2026 17:00:07 IST

Navin Fluorine’s new Surat HFC unit begins commercial operations

Mumbai-based Navin Fluorine International has begun commercial operations at its new hydrofluorocarbon (HFC) plant at Surat in Gujarat....

PRINT EDITION

View Past Issues

Search For

Exhibitions & Conferences

ChemExpo IndiaChemProTechChemLogistics India

Watch

KKBangEchemiGPCA ForumCPHI PMEC INDIA